12.16
+0.53(+4.56%)
Currency In USD
| Previous Close | 11.63 |
| Open | 11.81 |
| Day High | 12.29 |
| Day Low | 11.75 |
| 52-Week High | 17.43 |
| 52-Week Low | 5.6 |
| Volume | 1.66M |
| Average Volume | 2.73M |
| Market Cap | 958.07M |
| PE | 5.5 |
| EPS | 2.21 |
| Moving Average 50 Days | 11.1 |
| Moving Average 200 Days | 11.28 |
| Change | 0.53 |
If you invested $1000 in CorMedix Inc. (CRMD) 10 years ago, it would be worth $1,286.77 as of January 05, 2026 at a share price of $12.16. Whereas If you bought $1000 worth of CorMedix Inc. (CRMD) shares 5 years ago, it would be worth $1,587.47 as of January 05, 2026 at a share price of $12.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developi
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
GlobeNewswire Inc.
Oct 31, 2025 12:30 PM GMT
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
GlobeNewswire Inc.
Oct 23, 2025 12:30 PM GMT
BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that De